ICD-10-CM Code for NASH
The ICD-10-CM code for non-alcoholic steatohepatitis (NASH) is K75.81 1.
Clinical Context and Coding Considerations
NASH represents the progressive, inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The diagnosis requires:
- ≥5% hepatic steatosis (documented by imaging or histology)
- Hepatocyte injury (ballooning degeneration)
- Lobular inflammation
- With or without fibrosis 2
Important Coding Distinctions
When coding for liver disease in this spectrum, recognize these key differences:
Simple steatosis (NAFL) differs from NASH in that it lacks hepatocyte ballooning and has minimal inflammation, carrying negligible risk of progression 3, 2. While the provided evidence doesn't specify a separate ICD-10 code for simple NAFL, K75.81 is specifically designated for the inflammatory form (NASH).
NASH with cirrhosis requires additional coding to capture the advanced fibrosis stage, as the K75.81 code alone does not convey cirrhosis status 2.
Clinical Documentation Requirements
For accurate coding with K75.81, documentation should ideally include:
- Exclusion of significant alcohol consumption (>21 drinks/week for men, >14 drinks/week for women) 4, 2
- Exclusion of other secondary causes of hepatic steatosis
- Evidence of metabolic risk factors (obesity, type 2 diabetes, dyslipidemia, hypertension) 5
- Liver biopsy confirmation when available, though clinical diagnosis based on imaging plus metabolic risk factors is increasingly accepted 5
Common Coding Pitfalls
Avoid using K75.81 for simple steatosis without inflammation - this overcodes the severity and may trigger inappropriate management pathways.
Document fibrosis stage separately when known, as this critically impacts prognosis and treatment eligibility. Patients with F2-F3 fibrosis may qualify for specific therapies like resmetirom 6, 7.
Ensure metabolic comorbidities are also coded (diabetes, obesity, dyslipidemia), as NASH is fundamentally a metabolic disease and these codes support the diagnosis and justify screening 5, 4.